225 related articles for article (PubMed ID: 30132833)
1. Whole exome and target sequencing identifies MAP2K5 as novel susceptibility gene for familial non-medullary thyroid carcinoma.
Ye F; Gao H; Xiao L; Zuo Z; Liu Y; Zhao Q; Chen H; Feng W; Fu B; Sun L; Jiang X; He D; Jiang H; Yang M; Li L; Chen F; Liu X; Li S; Li Z; Jiang Y; Cheng L; Bu H
Int J Cancer; 2019 Mar; 144(6):1321-1330. PubMed ID: 30132833
[TBL] [Abstract][Full Text] [Related]
2. Clinical and Genetic Features of a Large Monocentric Series of Familial Non-Medullary Thyroid Cancers.
Cirello V; Colombo C; Karapanou O; Pogliaghi G; Persani L; Fugazzola L
Front Endocrinol (Lausanne); 2020; 11():589340. PubMed ID: 33488516
[TBL] [Abstract][Full Text] [Related]
3. Identification of
Marques IJ; Gomes I; Pojo M; Pires C; Moura MM; Cabrera R; Santos C; van IJcken WFJ; Teixeira MR; Ramalho JS; Leite V; Cavaco BM
Thyroid; 2021 Sep; 31(9):1366-1375. PubMed ID: 33906393
[No Abstract] [Full Text] [Related]
4. Absence of the MAP2K5 germline variants c.G961A and c.T1100C in a wide series of familial nonmedullary thyroid carcinoma Italian families.
Cirello V; Colombo C; Persani L; Fugazzola L
Int J Cancer; 2019 Jul; 145(2):600. PubMed ID: 30828786
[No Abstract] [Full Text] [Related]
5. Authors' reply to: Absence of the MAP2K5 germline variants c.G961A and c.T1100C in a wide series of familial non-medullary thyroid carcinoma Italian families. International Journal of Cancer 2019; in press.
Ye F; Gao H; Xiao L; Ding H; Huang Z; Jiang Y; Cheng L; Bu H
Int J Cancer; 2019 Jul; 145(2):601-602. PubMed ID: 30828792
[No Abstract] [Full Text] [Related]
6. Germ-line mutations in
Zhao Y; Yu T; Sun J; Wang F; Cheng C; He S; Chen L; Xie D; Fu L; Guan X; Yan A; Li Y; Miao G; Zhu X
Proc Natl Acad Sci U S A; 2021 Aug; 118(31):. PubMed ID: 34326253
[TBL] [Abstract][Full Text] [Related]
7. Novel Susceptibility Genes Drive Familial Non-Medullary Thyroid Cancer in a Large Consanguineous Kindred.
Majdalani P; Yoel U; Nasasra T; Fraenkel M; Haim A; Loewenthal N; Zarivach R; Hershkovitz E; Parvari R
Int J Mol Sci; 2023 May; 24(9):. PubMed ID: 37175943
[TBL] [Abstract][Full Text] [Related]
8. Identification of Rare Variants Predisposing to Thyroid Cancer.
Wang Y; Liyanarachchi S; Miller KE; Nieminen TT; Comiskey DF; Li W; Brock P; Symer DE; Akagi K; DeLap KE; He H; Koboldt DC; de la Chapelle A
Thyroid; 2019 Jul; 29(7):946-955. PubMed ID: 30957677
[No Abstract] [Full Text] [Related]
9. Identification of susceptibility gene mutations associated with the pathogenesis of familial nonmedullary thyroid cancer.
Zhu J; Wu K; Lin Z; Bai S; Wu J; Li P; Xue H; Du J; Shen B; Wang H; Liu Y
Mol Genet Genomic Med; 2019 Dec; 7(12):e1015. PubMed ID: 31642198
[TBL] [Abstract][Full Text] [Related]
10. [Next generation sequencing technology for susceptible gene screening in familial non-medullary thyroid carcinoma].
Dong L; Yu Y; Yu JP; Hao WJ; Zheng XQ; Cheng YN; Han L; Zhao JZ; Gao M
Zhonghua Zhong Liu Za Zhi; 2017 Jan; 39(1):24-28. PubMed ID: 28104029
[No Abstract] [Full Text] [Related]
11. CHEK2 germline variants identified in familial nonmedullary thyroid cancer lead to impaired protein structure and function.
Pires C; Marques IJ; Valério M; Saramago A; Santo PE; Santos S; Silva M; Moura MM; Matos J; Pereira T; Cabrera R; Lousa D; Leite V; Bandeiras TM; Vicente JB; Cavaco BM
J Biol Chem; 2024 Mar; 300(3):105767. PubMed ID: 38367672
[TBL] [Abstract][Full Text] [Related]
12. Identification of a Novel Germline
Hu Y; Han Z; Guo H; Zhang N; Shen N; Jiang Y; Huang T
Biomedicines; 2024 Jan; 12(1):. PubMed ID: 38275415
[TBL] [Abstract][Full Text] [Related]
13. Diagnosis and Management of Hereditary Thyroid Cancer.
Bano G; Hodgson S
Recent Results Cancer Res; 2016; 205():29-44. PubMed ID: 27075347
[TBL] [Abstract][Full Text] [Related]
14. Mutant MYO1F alters the mitochondrial network and induces tumor proliferation in thyroid cancer.
Diquigiovanni C; Bergamini C; Evangelisti C; Isidori F; Vettori A; Tiso N; Argenton F; Costanzini A; Iommarini L; Anbunathan H; Pagotto U; Repaci A; Babbi G; Casadio R; Lenaz G; Rhoden KJ; Porcelli AM; Fato R; Bowcock A; Seri M; Romeo G; Bonora E
Int J Cancer; 2018 Oct; 143(7):1706-1719. PubMed ID: 29672841
[TBL] [Abstract][Full Text] [Related]
15. Targeted DNA Sequencing Detects Mutations Related to Susceptibility among Familial Non-medullary Thyroid Cancer.
Yu Y; Dong L; Li D; Chuai S; Wu Z; Zheng X; Cheng Y; Han L; Yu J; Gao M
Sci Rep; 2015 Nov; 5():16129. PubMed ID: 26530882
[TBL] [Abstract][Full Text] [Related]
16. Penetrance of a rare familial mutation predisposing to papillary thyroid cancer.
Saporito D; Brock P; Hampel H; Sipos J; Fernandez S; Liyanarachchi S; de la Chapelle A; Nagy R
Fam Cancer; 2018 Jul; 17(3):431-434. PubMed ID: 29027612
[TBL] [Abstract][Full Text] [Related]
17. Genetic Mutations and Variants in the Susceptibility of Familial Non-Medullary Thyroid Cancer.
Miasaki FY; Fuziwara CS; Carvalho GA; Kimura ET
Genes (Basel); 2020 Nov; 11(11):. PubMed ID: 33218058
[TBL] [Abstract][Full Text] [Related]
18. Identification of a novel germline FOXE1 variant in patients with familial non-medullary thyroid carcinoma (FNMTC).
Pereira JS; da Silva JG; Tomaz RA; Pinto AE; Bugalho MJ; Leite V; Cavaco BM
Endocrine; 2015 May; 49(1):204-14. PubMed ID: 25381600
[TBL] [Abstract][Full Text] [Related]
19. Familial non-medullary thyroid cancer: unraveling the genetic maze.
Peiling Yang S; Ngeow J
Endocr Relat Cancer; 2016 Dec; 23(12):R577-R595. PubMed ID: 27807061
[TBL] [Abstract][Full Text] [Related]
20. Familial non-medullary thyroid carcinoma: clinico-pathological features, current knowledge and novelty regarding genetic risk factors.
Cirello V
Minerva Endocrinol (Torino); 2021 Mar; 46(1):5-20. PubMed ID: 33045820
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
